ELIC — Elicera Therapeutics AB Balance Sheet
0.000.00%
- SEK45.27m
- SEK4.56m
- SEK11.23m
Annual balance sheet for Elicera Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | — | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.034 | 11.6 | 52.4 | 43.8 | 29.4 |
Net Total Receivables | 0.051 | 0.446 | 0.204 | 1.98 | 0.784 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.085 | 12.1 | 54.2 | 45.8 | 30.2 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 0.618 | 12.6 | 54.7 | 46.3 | 30.2 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.004 | 2.35 | 2.5 | 13.5 | 13.8 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.004 | 2.35 | 2.5 | 13.5 | 13.8 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 0.614 | 10.2 | 52.2 | 32.8 | 16.4 |
Total Liabilities & Shareholders' Equity | 0.618 | 12.6 | 54.7 | 46.3 | 30.2 |
Total Common Shares Outstanding |